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Background: Current guidelines suggest specific criteria for oral or long-acting injectable antipsychotic drugs (LAIs).
This review aims to describe the demographic and clinical characteristics of the ideal profile of the patient with
schizophrenia treated with LAIs, through the analysis of nonrandomized studies.
Methods: A systematic review of nonrandomized studies in English was performed attempting to analyze the
factors related to the choice and use of LAIs in daily practice. The contents were outlined using the Cochrane
methods for nonrandomized studies and the variables included demographic as well as clinical characteristics. The
available literature did not allow any statistical analysis that could be used to identify the ideal profile of patients
with schizophrenia to be treated with LAIs.
Results: Eighty publications were selected and reviewed. Prevalence of LAI use ranged from 4.8% to 66%. The only
demographic characteristics that were consistently assessed through retrieved studies were age (38.5 years in the
1970’s, 35.8 years in the 1980’s, 39.3 years in the 1990’s, to 39.5 years in the 2000’s) and gender (male > female).
Efficacy was assessed through the use of various symptom scales and other indirect measurements; safety was
assessed through extrapyramidal symptoms and the use of anticholinergic drugs, but these data were inconsistent
and impossible to pool. Efficacy and safety results reported in the different studies yielded a good therapeutic
profile with a maximum of 74% decrease in hospital admissions and the prevalence of extrapyramidal symptoms
with LAIs consistently increased at 6, 12, 18, and 24 months (35.4%, 37.1%, 36.9%, and 41.3%, respectively).
Conclusions: This analysis of the available literature strongly suggests that further observational studies on patients
with schizophrenia treated with LAIs are needed to systematically assess their demographic and clinical
characteristics and the relationships between them and patient outcome.
Besides the good efficacy and safety profile of LAIs, health care staff must also take into account the importance of
establishing a therapeutic alliance with the patient and his/her relatives when selecting the most appropriate
treatment. LAIs seem to be a good choice not only because of their good safety and efficacy profile, but also
because they improve compliance, a key factor to improving adherence and to establishing a therapeutic alliance
between patients with schizophrenia, their relatives, and their health care providers.
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Schizophrenia is a chronic disabling illness with a world-
wide lifetime prevalence of about 1% [1]. It is character-
ized by relapses alternating with periods of partial or full
remission [2] and poor adherence to antipsychotic treat-
ment, leading to multiple rehospitalizations [3] and
increased direct and indirect costs [4-11].
Antipsychotic medications have evolved in order to
achieve a better control of schizophrenia. Long-acting
injectable antipsychotic drugs (LAIs), introduced for the
first time in the 1960’s, demonstrated their benefits by
lowering relapse rates and durations of hospitalization
[3,12-14], although the high prevalence and severity of
extrapyramidal symptoms (EPS) made it necessary to de-
velop new treatments. Second-generation antipsychotics
(SGAs) provided a better tolerability profile compared to
the first-generation antipsychotics (FGAs), but a high
nonadherence rate was still observed [15]. About 57% of
outpatients treated with oral SGAs adhere to the therapy
after 6 months [16]. The efficacy and safety of LAIs have
been well established through several randomized con-
trolled trials and therapy choice criteria for these
patients have been published recently [17], categorized
by disease severity, patients’ socioeconomic level, and
patients’ autonomy.
The recently released LAI SGAs provide the same fa-
vorable profile of oral SGAs, with an increased likeli-
hood of improving antipsychotic treatment adherence
[3,13].
To determine the ideal profile of the patient suitable
for treatment with LAIs, several characteristics should
be analyzed in order to understand which of these will
predict a better clinical outcome. Relevant information
about all these characteristics is available in the litera-
ture and important associations between these and LAIs
have been established. These features include the follow-
ing: compliance with and adherence to the treatment
[18-21]; attitudes of psychiatrists [22-25], relatives [26],
and/or patients [27,28] towards antipsychotic medica-
tion; patients’ insight about the disease [29-34]; history
of relapses [35]; previous treatment with antipsychotic
medication [36]; number of previous hospitalizations
[3,37]; duration of illness [31]; presence of positive [35]
and/or negative [38,39] symptoms; medication-related
adverse events [31,40]; and patient experience with
medication [41], among others.
Additionally, demographic features such as age, gen-
der, ethnicity, educational background, insurance cover-
age, polypharmacy, and history of substance abuse
should also be taken into account when considering
treatment with LAIs [40,42-48].
The ideal candidate for LAI treatment should be a
patient who has an unsatisfactory adherence to treat-
ment and who needs to follow a treatment planensuring adequate control of the disease, fewer
relapses, and good adherence to the treatment—factors
that will translate into a better quality of life (QoL),
fewer adverse events, fewer rehospitalizations, and a
comprehensive improvement. To achieve this goal, a
holistic approach has to be established with the aid of
health care personnel, patient relatives, and the
patients themselves.
The aim of this systematic review is to describe the
profile of the ideal patient with schizophrenia to be trea-
ted with LAI through the naturalistic observation of age,
gender, ethnicity, adherence to and compliance with LAI
by both patient and physician and their relative percep-
tion of LAI together with treatment efficacy and safety
profile.Methods
Study design
A systematic literature review [49] was performed on
the data reported in nonrandomized studies for the use
of LAIs. The contents of this systematic review were
outlined using Cochrane methods for nonrandomized
studies [50] in line with the Meta-analysis of Observa-
tional Studies in Epidemiology (MOOSE) methods [51].
Nonrandomized studies were chosen because rando-
mized clinical trials, having strict inclusion and exclusion
criteria, are not likely to assess clinical judgment of the
physicians in the routine clinical practice regarding
patients suitable for LAI treatment.Search strategy
A comprehensive literature search of the Medline (dat-
ing back to 1966), Embase (dating back to 1988), and
Cochrane (dating back to 1964) databases was con-
ducted using the OvidSPW interface (Ovid Technolo-
gies, Inc.; New York, NY) on May 15, 2011 by the
medical information team at Primo Scientific Corpor-
ation (Panama City, Panama). The search strategy and
results are summarized in Figure 1A. All the possible
combinations of the key terms “neuroleptic agent” or
“antipsychotic” and “depot” or “long-acting” or “inject-
able” or “extended release” were employed to obtain
relevant reports, regardless of their publication type.
The search was then restricted to nonrandomized
studies published in English, reporting information on
the use of LAIs for the different study variables fulfill-
ing the inclusion criteria (ie, patient demographics; ad-
herence to and compliance with LAI treatment;
physician, patient, and relatives perception of LAIs;
and the efficacy and safety profiles of LAIs). All the
electronic or hard copy publications were retrieved by
the library staff of Eli Lilly and Company (Indianapolis,
Figure 1 Search strategy and results. A. Search strategy and
results in the OVID interface. B. Study selection and results
algorithm.
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with the authors were required.Inclusion and exclusion criteria
Inclusion criteria were nonrandomized studies (retro-
spective or prospective, observational, open-label, mir-
ror-image, before and after, and/or case reports/series)
in English about the use of LAIs in patients with schizo-
phrenia, schizophreniform disorder, or schizoaffective
disorder.
Studies were excluded if they were randomized or
double-blind; investigated only pharmacokinetic or phar-
macodynamic characteristics of LAIs; patients included
were not treated by their psychiatrist according to usual
clinical practice; and/or if patients had other psychiatric
pathologies.
A flow chart is presented in Figure 1B to illustrate the
study selection process and results. A detailed list of the
studies included is presented in the Additional file 1.
Abstracts and full-text articles were screened according
to the inclusion and exclusion criteria and the publica-
tion full texts were retrieved for those matching the in-
clusion criteria. Various settings (eg, hospital-based LAI
clinics, outpatient clinics) in different countries and
populations (eg, young populations, patients in prison,
pregnant women) were included in the nonrandomizedstudies, as these were not restricted by the inclusion
criteria.
Statistical analysis
A formal meta-analysis was not performed because only
gender and age were consistently reported throughout
the studies and these two characteristics have poor prog-
nostic value to determine which patients benefit the
most from the use of LAIs.
The available literature did not allow any statistical
analysis that could be used to identify the ideal profile of
patients with schizophrenia to be treated with LAIs.
Only five of the publications retrieved (all publications
derived from the European Schizophrenia Outpatient
Health Outcomes [SOHO], a large observational study)
included both patients using LAIs and patients using dif-
ferent oral antipsychotics [52-56]. This study did not re-
port any statistical comparisons to assess differences in
clinical or demographic characteristics between the two
cohorts.
All of the studies retrieved were grouped per publica-
tion decade, and the weighted mean age of patients
using LAIs was calculated for each decade to assess a
possible trend.
Limitations of the study
1) Study presents nonrandomized studies for the use of
LAIs published in English
2) Literature available at resources Medline (dating
back to 1966), Embase (dating back to 1988), and
Cochrane (dating back to 1964) databases was used
in this study
3) There are inconsistencies in reporting the drugs and
dosages (in terms of absolute drug concentrations
and mg of chlorpromazine equivalents [CPZE]) used
in the different studies
4) Formal quality assessment of study could not be
done as studies included are narrative in nature
5) Only gender and mean age are consistently reported
among majority of the studies considered
6) Possible selection and information biases may exist
as data are derived from nonsystematic,
nonrandomized allocation to treatments and the
existence of unobserved covariates that might have
influenced the outcome
7) Some results were reported in only one paper and
thus they must be interpreted/taken with caution
Results
Eighty publications were included in this analysis (Add-
itional file 1). Several studies assessed the prevalence of
LAI use among patients with schizophrenia, which ran-
ged from 11.9% to 66.0% [44,45,47,55,57-61]. Because of
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in the different studies, it was not possible to perform
comparisons regarding the doses of LAIs. As this study
is narrative in nature [49], demographic and clinical
characteristics were grouped without a formal assess-
ment of study quality. All of the studies reporting either
type of factors were included and discussed. With these
findings in mind, identifying the characteristics of the
ideal profile of the patient to receive treatment with
LAIs entails analyzing several key demographic and clin-
ical variables, trying to assess the main aspects of effi-
cacy and safety of these drugs.
Demographic aspects
Only gender and mean age were consistently reported
in all of the studies, while other demographic factors
were scarcely or inconsistently reported. The studies by
Lindström et al., (1996) [57] and Sim et al., (2004) [58]
report a higher proportion of male patients (58.15%
[57]; 55.9% [58]) treated with LAIs as compared to
females (41.85%; 44.1%) [57,58]. The calculated mean
weighted age at treatment has been mostly stable
throughout the decades, from 38.5 years in the 1970’s,
35.8 years in the 1980’s, 39.3 years in the 1990’s, to
39.5 years in the 2000’s. One article [62] reported that
older age was associated with lower doses of LAIs
(275 ± 239 mg CPZE) and, though no significant correl-
ation of age with LAI daily dose for either haloperidol
decanoate (28 days 3.5 ± 2.5 mg; p = .50) or fluphenazine
decanoate (16 days 1.5 ± 1.3; p = .70) was found, a
pooled analysis of LAIs revealed that patients using
them in low doses (≤300 mg CPZE) were significantly
older (p = .005) [44].
In terms of ethnicity, another study [47] reported that
African American descent is a stronger predictor of
FGA use (odds ratio [OR] 1.53; 95% confidence interval
[CI] 1.12-2.09), at 53% higher doses (>1000 mg CPZE)
than other ethnic groups [48], but less likely (p<.001) to
receive LAIs or oral SGAs.
Results of a prospective comparative study of treat-
ment for schizophrenia conducted from 1997 to 2003 in
the use of first-generation depot antipsychotic at any
time during the three-year study (N= 569) and those
treated with only oral antipsychotics (N = 1,617) showed
a low-education background (p<.001) and poor insur-
ance coverage (p = .009) and further these were also
reported to be significantly different among patients
using LAIs versus oral antipsychotics (75% vs. 66% and
6% vs. 8%) [47]. Polypharmacy was also frequently
reported [44] in patients with schizophrenia on LAI
treatment and is a predictor for lower doses of anti-
psychotic drugs (OR 0.42; 95% CI 0.40-0.44; p<.001).
Remington et al. [63] found differences in the setting
where patients were treated: a large provincial hospitalwith 325 beds mostly devoted to treating patients with
schizophrenia used significantly higher doses (p = .05) of
antipsychotic drugs (N = 58; dose 773.8 ± 784.6 mg
CPZE) when compared to a university-affiliated psychi-
atric teaching hospital with 85 beds (N= 52; dose
424.8 ± 317.2 mg CPZE), and to a 25-bed inpatient psy-
chiatric unit (N= 53; dose: 355 ± 283.1 mg CPZE), re-
spectively. Conventional and depot antipsychotic
medication were the ones mostly used at provincial hos-
pitals (99%; 43%), while the novel antipsychotics were
the most commonly used at university and community
hospitals (56%; 55%) [63]. Patients on LAIs were also
found to receive higher doses of neuroleptic drugs in
terms of chlorpromazine equivalent doses (525 mg
CPZE; p<.001) [61].
Clinical aspects
Several key clinical elements are reported as being asso-
ciated with the use of antipsychotic treatment for
schizophrenia.
Perception of LAIs
Less than 20% of patients with schizophrenia receive
LAIs and less than 10% of psychiatrists offer LAIs after a
first psychotic episode, prescribing them in a very con-
servative manner and only when other therapeutic
options have failed [26], even though there is no evi-
dence supporting this practice [64]. It is important to
note that psychiatrists have decreased their LAI pre-
scribing rates in the last five years by approximately
50%, although LAIs are shown to be very efficacious, are
associated with higher compliance rates, and are cur-
rently more available [25]. A questionnaire-based survey
of 198 German psychiatrists found that LAI was only
prescribed to 13.3% out of 26.7% of patients with first
episode schizophrenia [65]. Principal reasons for lower
prescription rate were: difficulty in presenting the bene-
fits of LAI to patients for first treatment option; poor
availability of the LAI version of risperidone, olanzapine
pamoate, and paliperidone palmitate [22,25,66], specific-
ally preferred second generation LAI antipsychotics
[AP2G] [67,68]; and lower preference of psychiatrists for
prescribing LAI due to perception of adverse effects of
depot antipsychotics and related impact on the relation-
ship with the patient [65].
Psychiatrists prescribe oral tablet antipsychotics 88%
of the time [26]. When LAIs are prescribed, SGAs are
preferred (66%) over FGAs for LAI-naïve patients [25].
There is a report of patients having lower relapse rates
after using LAI risperidone after 2 years of treatment
following their first episode of psychosis [64].
Regarding patient attitudes toward LAI formulations,
24% of patients reported LAIs as their first choice of
treatment, while 88% reported the acceptance of oral
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when the patients are separated into three different
groups (LAI-naïve patients, patients currently receiving
LAIs, and patients previously treated with LAIs). LAI-
naïve patients preferred oral tablets over LAIs (94% vs.
23%), whereas patients on LAI treatment chose it over
oral tablets (73% vs. 67%). Compared to LAI-naïve
patients, patients with previous LAI experience chose
LAI more often, but curiously, had a greater preference
for tablet formulations [36].
The results from a clinical survey evaluating the pre-
scription rate of antipsychotics by psychiatrists corrobo-
rated the belief that patients with a poor course of
schizophrenia fit the ideal profile to receive LAI treat-
ment [69].
Patients with a better course of illness are character-
ized by having good insight about their illness, high edu-
cational levels, high levels of participation in treatment
decisions, knowledge of their condition, and a desire to
maintain a therapeutic alliance with the psychiatrist. A
new approach could also include these patients as candi-
dates to receive LAIs [45]. Many studies have reported
that patients with better relationships with their physi-
cians have better compliance rates compared to those
with “fair” or “poor” relationships (74% vs. 26%, respect-
ively) [21,70].
There is a high prevalence of poor insight among
patients with schizophrenia [71]. Poor insight is the
most common symptom of schizophrenia [34]; approxi-
mately 57% of patients are moderately or severely un-
aware of having a mental illness [33]. Poor insight has
been related to poor compliance [72], which is the main
cause of nonadherence to treatment in patients with
schizophrenia [73]. The consequences of poor patient
insight about their illness are reflected in a greater risk
of relapse and more frequent and longer hospital admis-
sions [21]. Treatment with LAI risperidone improved
insight scores in patients previously treated with oral
SGAs or typical LAIs. Additionally, insight improvement
corresponded to favorable changes in other symptom
domains, such as the Positive and Negative Symptoms
Scale (PANSS) and the Clinical Global Impression
(CGI)-Severity subscale [71].
Adherence to and compliance with LAI treatment
Nonadherence rates with antipsychotics are often
reported as being 40%-60% [74,75]. When comparing
treatment adherence to preference between patients on
oral antipsychotic tablets or LAIs, patients prescribed
with LAIs were significantly more compliant than those
receiving oral antipsychotics [11,27,40,76-78]. Figure 2
presents an algorithm of compliance predictors, that can
help the mental-health specialists choose the best next
step in the management of patients with schizophreniaon treatment, taking into consideration the most rele-
vant aspects found in the literature. These predictors
must be incorporated into the concept that all those
involved in the integral care of the patient with schizo-
phrenia must engage in a therapeutic alliance [21].Efficacy
The efficacy of LAIs in general, and SGAs in particular,
seems to be consistently shown throughout studies
where patients reported improvement on the most com-
mon efficacy measures.
One such measure is the CGI scale, which has become
one of the most widely used assessment tools in psych-
iatry since it was first published [79]. A greater baseline
overall CGI score was found to be a predictor of discon-
tinuation for antipsychotic medication [54]. Studies re-
port that CGI scales significantly improved in patients
using LAI SGAs [52,53,55,56,80], zuclopenthixol decan-
oate [81], perphenazine decanoate [82,83], or LAI risper-
idone [84,85]. PANSS, which is not an outcome rating
instrument per se, but originated from the growing need
to reduce the heterogeneity of what was known about
schizophrenia, [86] was also used in observational stud-
ies [87]. PANSS score also consistently improved in
studies where LAI risperidone was used [88,89]. The
Comprehensive Psychiatric Rating Scale (CPRS) has also
been used in another study [90], reporting significant
correlations (p<.001) with the serum levels of zuclo-
penthixol decanoate.
Other authors have attempted to evaluate the QoL
experienced by patients using LAIs. This has been
assessed by different studies using various scales, such
as the Global Assessment of Functioning (GAF), the
Short Form Health Survey (SF-36), and the EuroQoL 5-
Dimensions Visual Analog Scale (EQ-VAS). Studies on
the use of LAIs in different settings have reported sig-
nificant improvements (p<.01) in the total GAF score
[47,79,91-94] or in the SF-36 overall score [95], as well
as in some of its items [71,84,91,93,96]. Although the
use of the EQ-VAS, another scale for assessing QoL
used through the SOHO cohorts, has not yielded sig-
nificant improvements in QoL for all pooled LAIs
[52,53], its baseline value has been found to be a signifi-
cant factor associated with achieving long-lasting symp-
tomatic remission (OR 1.026; 95% CI not reported;
p<.0001) [56].
An indirect measurement of efficacy is the hospitalization
rate which, despite having different operational definitions,
improved in patients treated with LAIs. Studies of treat-
ment with LAIs consistently report significant decreases in
the different quantifiers expressing the length of
hospitalization (ie, absolute hospital days, days per patient,
number of hospitalizations, bed-days per patient, or
Figure 2 Decision algorithm for choosing a long-acting antipsychotic based on treatment compliance predictors reported in the
literature.
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Only one small study (n= 46) found no statistical differ-
ences in rehospitalization rates between patients using oral
antipsychotics versus LAIs [107]. A greater length of
hospitalization was related to an increased number of pre-
scriptions of LAIs versus oral antipsychotics and the his-
tory of psychiatric hospitalization in the prior year was a
predictor of LAI FGA use [47]. The frequency of previous
admissions was a predictor of rehospitalizations in a one-
year observational trial [98]. The annual risks of readmis-
sion for patients using fluphenazine decanoate or halo-
peridol decanoate were 21% and 35%, respectively [46]
and a decrease in rehospitalization rates was reported in
studies with LAI fluphenazine (74% decrease in hospital
admissions compared with previous treatment) [105], per-
phenazine (59% decrease in relative risk compared with
haloperidol) [108]; and LAI risperidone (27% reduction in
hospitalization rates) [9]. Patients using haloperidol decano-
ate presented statistically significantly greater differences in
rehospitalization risk when compared to oral risperidone
(Holm’s adjusted p= .001), olanzapine (Holm’s adjusted
p= .0008), and clozapine (Holm’s adjusted p= .049) [46].
Frequency of hospitalizations was positively related with
duration of illness, with current dose of neuroleptics (i.e.,
fluphenazine), and with overall neuroleptic exposure [109].Safety
Many patients switching to LAI risperidone after treat-
ment with conventional antipsychotics showed a signifi-
cant improvement in EPS, measured primarily by the
Extrapyramidal Symptom Rating Scale (ESRS)
[90,91,93,95,96,110-113]. The ESRS has also been used in
patients treated with perphenazine decanoate [82,83] and
fluphenazine decanoate [114] with similar results. When
the Drug-Induced EPS Scale (DIEPSS) was applied to
patients treated with LAI risperidone, no significant differ-
ences were found in the rate of EPS [94]. In the SOHO
study [53], the prevalence of EPS in the Italian cohort trea-
ted with LAIs consistently increased at 6, 12, 18, and
24 months (35.4%, 37.1%, 36.9%, and 41.3%, respectively).
In the same cohort, the proportion of EPS at 12 months
was significantly higher in patients treated with typical
LAIs (32%) and oral typical antipsychotics (30%) com-
pared to risperidone (16%), quetiapine (10%), clozapine
(9%), and olanzapine (8%) [52]. Among patients with or
without EPS treated with typical LAIs, the GAF and total
BPRS scores differed at hospital discharge [115]. An indir-
ect measure of EPS is the use of anticholinergic drugs,
which was reported as significantly higher in patients
using LAIs (47%) compared with patients using oral SGAs
(13%) [116] and has a rate ranging from 30.9% to 32.0%
Rossi et al. BMC Psychiatry 2012, 12:122 Page 7 of 13
http://www.biomedcentral.com/1471-244X/12/122for overall LAIs [52,117]. Lower values of anticholinergic
drug use were reported in patients using LAI risperidone
(5.2%) [118] and higher values were reported in those
using fluphenazine decanoate (67.0%) [114]. Common
EPS and non-EPS adverse events and their frequencies are
summarized in Tables 1 and 2, respectively. The largest re-
port on prolactin-related adverse events was found in the
Italian cohort of the SOHO study (n= 3016) [52] after
12 months of treatment with different antipsychotic drugs
(risperidone, quetiapine, clozapine, typical oral anti-
psychotic drugs, and typical LAI). A significant proportion
of patients using typical LAIs reported prolactin-related
adverse events, the most common being loss of libido,
which was reported by 38.1% of these patients.
For LAIs, small but statistically significant increases in
body weight and BMI have been reported; contrasting
reports of nonsignificant increases in these parameters
were also found in the literature (Table 3). These weight
and BMI increases were not dose-dependent [117].
Pain caused by injections is another safety measure
reported that is most often evaluated through the visual
analog scale (VAS). One study [119] found that zuclo-
penthixol injections were significantly more painful than
flupenthixol, fluphenazine, and haloperidol and that pain
score measured by VAS was correlated to the Hamilton
Scale for Depression (HAM-D). Another study found
that injection-site pain with LAI risperidone significantly
decreased over 50 weeks [96]. An additional LAI pooled
study (haloperidol, fluphenazine, zuclopenthixol, and flu-
penthixol) found no significant correlation between VAS
measures 5 minutes after the injection, but found a sig-
nificant correlation after 2 days of the injection adminis-
tration [119]. No relationship was found between VAS
pain score, patient weight, or the score in the Udvalg for
Kliniske Undersøgelser (UKU) 48-Item Side-Effect Rat-
ing Scale [8].
Some studies report the results while using LAIs in
peculiar situations. One report [120] on the use of LAI
risperidone during pregnancy was found, and it did not
report any immediate complication at birth. Another
study [121] found that mean serum copper levels wereTable 1 Percentages of extrapyramidal adverse events report
Drug FL FE R R R
Reference [131] [132] [80] [132] [90]
n 16 5 19 87 249
Dystonia — — — 1.1 —
Akathisia 12.5 40.0 5.3 2.3 2.0
Parkinsonism/tremor 6.2 — — 4.6 —
Tardive dyskinesia — — — 3.4 —
Hypertonia — — — 2.3 —
Abbreviations: Z= zuclopenthixol decanoate; R= risperidone; y= in young patients; a
antipsychotic drugs; —=not reported.significantly (p = .004) higher in patients treated with flu-
phenazine decanoate (117.4 μg/dL; 95% CI 111.2-
123.6 μg/dL) versus healthy controls (105.6 μg/dL; 95%
CI 96.9-114.2 μg/dL); mean serum zinc levels did not
differ between the two groups.Discussion
Long-acting injectable antipsychotic drugs were devel-
oped to become a therapeutic option especially for those
patients where nonadherence is a major clinical concern,
with consequences of subsequent relapse episodes and
rehospitalizations [46,122,123]. Although there is a
strong, but perhaps misguided, belief that LAIs cannot
be used as first-line treatment for schizophrenia, new
guidelines state that the clinician should consider offer-
ing them to LAI-naïve patients with schizophrenia [124-
131].
The most favorable conditions for the development of
an effective therapeutic alliance occur in patients who
are well-informed about their illness and are compliant
with treatment, in conjunction with medical staff who
are willing to provide explanations and to offer a holistic
therapeutic approach [132-134]. This type of therapeutic
alliance promotes the patient’s adherence to their treat-
ment and facilitates open lines of communication, so
that patients can meaningfully participate in treatment
decisions.
Even though nonrandomized studies have some well-
known limitations (uncertainty of data collected, differ-
ences in their design and implementation, lower level of
evidence than randomized controlled studies, and not
being included in study registries) [50], they are the only
studies in which patients were enrolled and treated
according to physicians’ clinical judgment. Consequently,
nonrandomized studies are the only studies that, in a
naturalistic setting, allow researchers to understand how
physicians, based on their clinical judgment, select
patients with schizophrenia who have the ideal profile
for LAI treatment and who should benefit the most from
it. Moreover, they provide naturalistic observation ofed for different long-acting antipsychotic drugs
R y R a R R P V V Z
[91] [91] [107] [133] [77] [8] [58] [76]
66 351 725 529 42 53 368 19
— — — — — 15.1 0.5 —
19.7 11.1 17.0 3.4 — 43.4 2.4 —
— — — 6.0 2.4 30.2 7.6 —
— — — — — — 3.0 15.8
— — — — — 24.5 — —
= in adult patients; FL= flupenthixol; FE= fluphenazine; V= various long-acting
Table 2 Percentages of the most frequent and selected general adverse events reported for different long-acting
antipsychotic drugs
Drug FL R R R R, in no r R in r R R vs oral R R R y R a R R R R V Z
Reference [131] [15] [79] [86] [84] [84] [85] [88] [89] [90] [91] [91] [105] [107] [132] [133] [88] [76]
n 16 715 192 202 312 82 1476 100 40 249 66 351 336 725 87 529 565 19
Anxiety 12.5 12 12 15 28.7 24.5 6.9 11.0 — 11 21 23 22.3 26 16.1 23.9 — —
Insomnia 6.2 10 9 9 26.5 25.0 7.0 9.0 5.0 6 29 19 23.5 22 16.1 18.7 — 8
Disease exacerbation — — 10 — 20.1 15.8 6.1 5.0 — 6 12 12 18.2 15 19.5 7.4 — —
Depressive reactions 17 — 6 — 19.8 15.7 — 5.0 — — 17 14 19.3 15 — 11.3 — 25
Headache — — — — 14.7 14.7 — — 2.5 6 21 11 — 11.5 7.7 — —
GI symptomsa — — — — — — — — — — 11 3 — — — — — 17
Glucose-related AEs — — — 0.5b — — — — — — — — — — 0.0 0.8c 0.0 —
Prolactin-related AEsd — — — 0.5 — — — 6.0 2.5f 2.8 — — — — — — 0.4e —
Sedation/Somnolence — — — — — — — — — — 12 5 — — — — — —
Rhinitis — — — — — — — — — — 18 11 — — — — — —
Fatigue — — — — — — — — — — 15 7 — — — — — —
Others 6.2h — — — — — — — 2.5g,h — — — — — — — — 17h
Abbreviations: FL= flupenthixol; R= risperidone; r= remission; y= in young patients; a= in adult patients; V= various; Z= zuclopenthixol decanoate;
GI=gastrointestinal; AEs= adverse events; —=not reported.
aIncludes dyspepsia, nausea, and vomiting.
bNew onset type 2 diabetes mellitus (n = 1).
cNew onset type 2 diabetes mellitus (n = 3) and hyperglycemia (n = 1).
dIncludes loss of libido, sexual impotence, galactorrhea, and gynecomastia.
eImpotence (n = 1) and galactorrhea (n = 1).
fIrregular menstruation (n = 1).
gDisturbances in accommodation.
hDizziness.
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by the physician as the most appropriate for each
patient.
We found no obvious explanation for the decrease in
the prescription rates of LAIs by psychiatrists
[25,57,135] even when LAIs have specific advantages
over oral FGAs and SGAs, especially in noncompliant
patients [136,137]. This could also be due to the percep-
tion that depots and LAIs are old-fashioned and they are
reserved for the most chronic and disabled patients
[138-140]. Furthermore, due to higher availability of oral
atypical antipsychotics in the 1990s, with associated
heavy marketing, the decline in prescription of depot
has continued due to the assumptions that patients al-
ways prefer oral to depots even though clinician’s atti-
tude towards these medications is marginally improved.
The adverse impacts of patient preference of depots to
LAIs, in relation to relapse prevention are rarely
explained and discussed with the patient [141]. A six-
month, open-label study with LAI risperidone in 382
patients with recent schizophrenia or schizoaffective dis-
order (diagnosed ≤3 years ago) showed significant de-
crease of severity of schizophrenic symptomatology in
73%: among these, in 40% of patients, total PANSS score
decreased by at least 20%. At the same time, patients
showed an improvement of overall functioning, qualityof life, and satisfaction [142,143]. These observations
suggest that there is a need for prescribing LAI for
effecting an increase in efficacy and functioning.
Even when the validity of using certain scales as effi-
cacy endpoint measurements has been criticized [86,87],
these and other efficacy endpoints such as good symp-
tomatic control, improved QoL, and reduced
hospitalization rates seem to be consistently achieved by
patients with schizophrenia treated with LAIs.
Safety, which can be evaluated using different tools,
might be a concern when considering the use of LAIs.
The frequency of EPS seems to be reduced when
patients switch from oral to LAIs and the most frequent
EPS reported were akathisia and parkinsonism/tremor
(Table 1). Tardive dyskinesia was generally reported less
frequently, but was more commonly reported in patients
using zuclopenthixol decanoate than those using LAI
risperidone or LAIs in general [81]. Other frequently
reported side effects of LAIs are anxiety, insomnia, dis-
ease exacerbation, depression, headache, and weight
gain, but the data retrieved cannot be considered con-
clusive. It is fundamental to consider side effects, since
patient attitude towards these strongly influence their at-
titude towards the entire treatment [8].
Unfortunately, the data reported in the literature
cannot be combined any further to identify the ideal
Table 3 Weight and BMI changes reported in selected LAI
publications






Risperidone [15] 715 1.4*** 0.5***
Various [48] 293 0.0a NR
Various [52] 176 0.1 NR
Various [53] 540 2.9b 0.7b
Various [55] 1173 NR 0.2b
Various [58] 2399 −1.0b NR
Various [61] 534 1.3c NR
Perphenazine [78] 42 No weight changed NR
Risperidone [79] 192 0.0 −0.1
Risperidone [85] 1476 0.9 0.3
Risperidone [86] 202 0.5 0.2
Various [88] 565 0.9* NR
Risperidone [90] 249 1.4*** 0.5***
Risperidone [105] 336 2.5 0.8
Risperidone [108] 50 NR 0.0
Various [112] 97 NR 1.5b
Risperidone [132] 67 −0.3 NR
Risperidone [133] 529 1.0*** 0.6***
Various [134] 5950 NR −0.7e
Abbreviations: BMI=body mass index; LAI= long-acting injectable
antipsychotic drugs; NR=not reported; pts=patients.
aPts treated with in-range chlorpromazine-equivalent doses versus patients
treated with higher chlorpromazine-equivalent doses.
bVersus oral antipsychotics.
cPts treated with LAI and anticholinergic drugs versus patients treated with LAI
without anticholinergic drugs.
dThis study reported no weight change, with 16 pts gaining a range of 1-9 kg
and 7 pts losing a range of 1-2 kg.
ePatients achieving persistent remission versus patients with prolonged
disease.
*p ≤ .05; ** p≤ .01; ***p≤ .001.
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http://www.biomedcentral.com/1471-244X/12/122profile of the patient using LAIs, due to the inconsist-
ency in the way the results are reported. Even those
variables, such as age and gender, reported in all
studies retrieved have poor prognostic value in terms
of understanding how physicians select the ideal pro-
file of the patient with schizophrenia to be treated
with LAIs. The only consistently reported reason why
certain patient profiles are identified as “ideal” to re-
ceive LAI treatment is because this type of adminis-
tration ensures treatment delivery. Patient insight,
attitude toward, and compliance with LAIs are crucial
factors that influence physician’s LAI choice, especially
when a good therapeutic alliance has been established
[69,144]. Nowadays, the therapeutic alliance seems to
be the most influential factor related to successful
compliance and adequate adherence to the schizo-
phrenia treatment [16,26,28,43,69]. This factor canimprove efficacy, safety, and cost-effectiveness out-
comes (Figure 2) [5-7,9,69,122].
Authors agree that the most common reason for pre-
scribing LAIs is noncompliance, but these drugs on their
own do not overcome the problem of treatment nonad-
herence. This is why therapeutic alliance plays a key role
[16,26,28,43,69]. Greater illness insight is related to bet-
ter attitudes toward treatment, improved compliance,
and fewer relapses and hospitalizations [29,30]. Patients’
and their relatives’ opinions must be taken into consider-
ation before initiating or switching to a new therapeutic
plan. A survey among patients with schizophrenia
revealed that 67% of them had not received any informa-
tion about LAI treatment from their psychiatrists [25].
Ultimately, patients have the right to make an informed
decision about LAI treatment. Its overall negative per-
ception could be reduced if psychiatrists were to provide
broader and more comprehensive information to
patients with schizophrenia and their relatives. Further-
more, patients’ decisions regarding treatment should be
guided by healthcare providers (Figure 3), after the most
relevant topics and concerns have been evaluated, dis-
cussed and understood by the patients and their
relatives.Conclusions
Though LAI prescription rates have been decreasing,
they still prove to have good efficacy and safety profiles.
The important question, therefore, is to determine which
patients with schizophrenia are the most suitable for
treatment with LAIs. Our research might reveals indica-
tors that could support psychiatrists tailor their answer
to this question when dealing with particular cases. Psy-
chiatrists seeking to improve the therapeutic alliance
with patients who need to improve treatment compli-
ance and adherence should consider LAIs when estab-
lishing a therapeutic plan. Efficacy and safety must also
be taken into account. Naturalistic setting trials aimed at
understanding how therapeutic alliance can be improved
by the use of LAIs should be carried out in order to sys-
tematically identify those patients who would most
benefit from the use of LAIs.Additional file
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